Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

作者全名："Huang, Linjuan; Zhang, Jing; Deng, Youling; Wang, Hao; Zhao, Piao; Zhao, Guozhi; Zeng, Wei; Wang, Yonghui; Chen, Connie; Wagstaff, William; Haydon, Rex C.; Reid, Russell R.; He, Tong-Chuan; Shen, Le; Luu, Hue H.; Zhao, Ling"

作者地址："[Huang, Linjuan; Zhang, Jing; Deng, Youling; Zhao, Piao; Zhao, Guozhi; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China; [Huang, Linjuan; Zhang, Jing; Deng, Youling; Zhao, Piao; Zhao, Guozhi; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China; [Huang, Linjuan; Zhang, Jing; Deng, Youling; Zhao, Piao; Zhao, Guozhi; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China; [Huang, Linjuan; Zhang, Jing; Deng, Youling; Wang, Hao; Zhao, Piao; Zhao, Guozhi; Zeng, Wei; Wang, Yonghui; Chen, Connie; Wagstaff, William; Haydon, Rex C.; Reid, Russell R.; He, Tong-Chuan; Shen, Le; Luu, Hue H.; Zhao, Ling] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA; [Wang, Hao] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China; [Wang, Hao] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China; [Zeng, Wei] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China; [Wang, Yonghui] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China; [Reid, Russell R.] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA; [He, Tong-Chuan; Shen, Le] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA"

通信作者："Zhao, L (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China."

来源：GENES & DISEASES

ESI学科分类：MOLECULAR BIOLOGY & GENETICS

WOS号：WOS:001017520200001

JCR分区：Q1

影响因子：6.9

年份：2023

卷号：10

期号：4

开始页：1687

结束页：1701

文献类型：Article

关键词：Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide; Ovarian cancer

摘要："Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc-tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag-nosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu-mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu-tic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic"

基金机构："National Institutes of Health [CA226303, DE030480]; Medical Scientist Training Program of the National Institutes of Health (USA) [T32 GM007281]; University of Chicago Cancer Center Support Grant [P30CA014599]; National Center for Advancing Translational Sciences of the National Institutes of Health (USA) [UL1 TR000430]; Mabel Green Myers Research Endowment Fund; University of Chicago Orthopaedics Alumni Fund"

基金资助正文："The reported work was supported in part by research grants from the National Institutes of Health (No. CA226303 to TCH, and No. DE030480 to RRR). WW was supported by the Medical Scientist Training Program of the National Institutes of Health (USA) (No. T32 GM007281). This project was also supported in part by The University of Chicago Cancer Center Support Grant (No. P30CA014599) and the National Center for Advancing Translational Sciences of the National Institutes of Health (USA) (No. UL1 TR000430). TCH was also supported by the Mabel Green Myers Research Endowment Fund and The University of Chicago Orthopaedics Alumni Fund.& nbsp;<STRONG>Funding & nbsp;</STRONG>sources were not involved in the study design, collection, analysis & interpretation of data, writing of the report, and the decision to submit the paper for publication."